Weekly Digest – May 2025 Weekly Digest – May 2025 08 May 2025: AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer in India AstraZeneca received CDSCO approval in India to import and sell […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: Adcentrx Therapeutics granted Fast Track Designation for ADRX-0706 nectin-4 ADC for the treatment of advanced cervical cancer Adcentrx Therapeutics received FDA Fast Track designation for its lead […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: IDEAYA Biosciences announces US FDA IND-clearance for IDE849, a potential first-in-class DLL3 TOP1 ADC, for a Phase 1 study in solid tumors IDEAYA Biosciences received FDA clearance […]
Weekly Digest – May 2025 Weekly Digest – May 2025 07 May 2025: ENHERTU (Trastuzumab deruxtecan) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer […]
Weekly Digest – May 2025 Weekly Digest – May 2025 05 May 2025: VERAXA Biotech enters co-discovery alliance with OmniAb for a novel bispecific antibody drug conjugate program VERAXA Biotech has entered into a co-discovery alliance with OmniAb to develop […]
Weekly Digest – May 2025 Weekly Digest – May 2025 06 May 2025: Formosa Pharmaceuticals and Almac Discovery announce licensing agreement for ALM-401, a first-in-class Bispecific ADC targeting EGFR/ROR1 for the treatment of solid tumors Formosa Pharmaceuticals has secured exclusive […]
Weekly Digest – May 2025 Weekly Digest – May 2025 1 May 2025: OBI Pharma announces U.S. FDA clearance of IND application for a Phase 1/2 study of OBI-902, a Trop-2 targeting ADC OBI Pharma received U.S. FDA clearance to […]
Weekly Digest – May 2025 Weekly Digest – May 2025 1 May 2025: The NMPA has granted breakthrough-therapy-designated drug for B7-H4-targeted antibody-drug conjugate HS-20089 Hansoh Pharmaceuticals B7-H4-targeted ADC, HS-20089, has been granted BTD by China’s National Medical Products Administration (NMPA) […]
Weekly Digest – May 2025 Weekly Digest – May 2025 28 Apr 2025: Orum Therapeutics provides program update and announces drug candidate nomination Orum Therapeutics has discontinued the clinical development of ORM-5029, its HER2-targeted degrader-antibody conjugate (DAC), following an internal […]
Weekly Digest – May 2025 Weekly Digest – May 2025 29 Apr 2025: Araris Biotech AG announces research agreement to develop next-generation ADCs using Araris’ AraLinQ technology Araris Biotech has signed a research agreement with Johnson & Johnson to develop […]
